A Hong Kong-led global study indicates that a targeted therapy can significantly extend progression-free survival for advanced lung cancer patients, potentially transforming the disease into a manageable chronic condition.

A Hong Kong co-led global study has found that a targeted therapy can keep more than half of advanced lung cancer patients alive without disease progression for at least seven years, marking a step towards turning the deadly illness into a chronic condition. Researchers from the Chinese University of Hong Kong on Wednesday released the findings of their study, which looked into the efficacy of the third-generation targeted therapy lorlatinib on patients with advanced lung cancer. The study...